Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Capital alliance formed to discuss iPS collaboration
May 2013
SHARING OPTIONS:

TOKYO—An agreement has been signed between Retina Institute Japan K.K. (RIJ) and Dainippon Sumitomo Pharma Co. Ltd. (DSP) regarding a DSP investment into RIJ. Per the terms of the agreement, DSP has subscribed for 1.5 billion yen of third-party allocation of shares by RIJ, and will exclusively discuss with RIJ the possibility of collaborating in and outside of Japan on induced pluripotent stem cell technology as a cure for age-related macular degeneration, a leading cause of blindness.
 
"The significance of this development cannot be underestimated," Dr. Hardy T. S. Kagimoto, president of RIJ, said in a press release. "It is a privilege for RIJ to have the opportunity to commercialize this exciting new technology and to transform the lives of millions of patients globally."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.